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To the Editor, 
In a recent study, authors described therapeutic options for Coronavirus Disease-19 (COVID-19) 
[1].  Histamine is an endogenous biogenic amine distributed ubiquitously in the body and is 
present in high concentrations in the lungs, skin, and gastrointestinal tract. It acts as a local 
mediator in the immune system. Histamine brings about complex physiologic changes, including 
chemotaxis, cytokine production, and gastric acid secretion. These biologic changes occur via 
four G protein–coupled receptor (GPCR) subtypes: H1 receptor (H1R), H2 receptor, H3 receptor, 
and H4 receptor (Table 1). H1R is expressed in various cell types, such as neurons, endothelial 
cells, adrenal medulla, muscle cells, hepatocytes, chondrocytes, monocytes, neutrophils, 
eosinophils, dendritic cells (DCs), T cells, and B cells.  H1R activation leads to activation of Th1 
lymphocytes, and decreased humoral immunity. H2R is expressed by parietal cells of the gastric 
mucosa, muscle, epithelial, endothelial, neuronal, hepatocyte, and immune cells. H2R 
antagonizes some of the effects mediated by H1R and leads to the relaxation of smooth muscle 
cells, causing vasodilation. In a murine lung inflammation model, H2R loss has an effect on 
invariant natural killer T (iNKT) cells, aggravating local inflammation [2]. 
H3R functions were identified in the central nervous system and peripheral and presynaptic 
receptors to control the release of histamine and other neurotransmitters. H4R is preferentially 
expressed in the intestine, spleen, thymus, bone marrow, peripheral haematopoietic cells, and 
cells of the innate and adaptive immune systems. Expression of H4R is regulated by stimulation 
with TNF-α, IL-6, IL-10, and IL-13, leading to inhibition of cAMP accumulation and activation 
of mitogen-activated protein kinases (MAPK) by H4R. 
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So histamine is a potent inflammatory mediator, commonly associated with allergic reactions, 
promoting vascular and tissue changes and possessing high chemoattractant activity.  The use of 
selective H4R ligands and/or modulation of H1 and H4 receptor synergism may be more 
effective in the treatment of inflammatory conditions of the lung.  Histamine also modulates the 
inflammatory response by acting on other cellular populations, in human lung macrophages.  The 
binding of histamine to H1R induces production of proinflammatory cytokine IL-6 and β-
glucuronidase. Blocking H4R in a model of pulmonary fibrosis alleviates the inflammatory 
response, reducing COX2 expression and activity, leukocyte infiltration, production of TGF-β 
(profibrotic cytokine), and collagen deposition.  
To date a few studies looking into the use of antihistamine products in patients with COVID-19. 
In self-administered high dose oral famotidine therapy, all 10 patients had marked improvements 
of COVID-19 symptoms [3]. Interestingly, analysis of pharmacokinetic parameters of famotidine 
might indicate that it needs to be given intravenously to be effective in COVID-19 treatment 
given its low gastrointestinal absorption and volume of distribution [4]. In propensity-score 
matched retrospective cohort study comparing famotidine cohort (84 patients) to non-famotidine 
cohort (1536 patients), a crude analysis showed that famotidine use was significantly associated 
with reduced risk for death and was independently associated with risk for death or intubation 
(adjusted hazard ratio (aHR) 0.42, 95% CI 0.21-0.85)  [5]. The famotidine group received 
between 10-40 mg/day for a median of 5.8 days, and 72% received it orally [5]. One limitation to 
recognize is the risk of unmeasured confounders, particularly that sicker patients might be more 
likely to receive proton-pump inhibitors than H2R blockers. Although famotidine is an H2R 
antagonist and used mainly for peptic ulcer and gastroesophageal reflux, its potential benefit was 
attributed to binding and inhibiting the 3-chymotrypsin-like protease [4]. There is currently one 
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ongoing double-blind randomized controlled trial in New York evaluating the efficacy of high 
dose intravenous famotidine (360 mg/day) with standard of care for a maximum of 14 days in 
hospitalized COVID-19 patients [6].  The H2R antagonists class also includes ranitidine 
cimetidine, and nizatidine. In allergic reactions, the preferred antihistamines target H1R [4]. 
Currently, we could not find studies evaluating the efficacy of H1R blockers in COVID-19.  
Histamine is a main mediator that is being released by immune system and other cells as a result 
of virus invasions or activation. Histamine initiates abnormal immune response leading to 
cytokine storm and multi-organs failure.  Thus, the use of antihistaminic medications could result 
in a significant immune modulation which may help in the treatment of cytokine storm of 
COVID-19.  Future studies could compare H2R antagonists with those of steroid therapy in 
addition to the effect of combination therapy in relation to standard therapy. 
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Table 1: Types and Functions of Different Histamine Receptors 
 Expression in Cell 
Types 
Function Available studies in relation 
to COVID-19 
Histamine 
1 
Receptor 
(H1R) 
neurons, 
endothelial cells, 
adrenal medulla, 
muscle cells, 
hepatocytes, 
chondrocytes, 
monocytes, 
neutrophils, 
eosinophils, 
dendritic cells 
(DCs), T cells, and 
B cells 
• activation of Th1 
lymphocytes, and 
decreased humoral 
immunity 
• none 
Histamine 
2 
Receptor 
(H2R) 
parietal cells of the 
gastric mucosa, 
muscle, epithelial, 
endothelial, 
neuronal, 
hepatocyte, and 
immune cells 
• antagonizes some of 
the effects mediated by 
H1R and leads to the 
relaxation of smooth 
muscle cells, causing 
vasodilation. 
• inhibition of CXCL10, 
• Observational 
studies [3][4][5]  
• Multi-site Adaptive 
Trials [6] 
•  
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IL-12, and TNF-α 
stimulation of IL-10, 
which is likely 
associated with Th2 
polarization 
Histamine 
3 
Receptor 
(H3R) 
identified in the 
central nervous 
system and 
peripheral and 
presynaptic 
receptors 
• control the release of 
histamine and other 
neurotransmitters 
• none 
Histamine 
4 
Receptor 
(H4R) 
preferentially 
expressed in the 
intestine, spleen, 
thymus, bone 
marrow, peripheral 
hematopoietic 
cells, and cells of 
the innate and 
adaptive immune 
systems.  
• Activation causes 
chemotaxis in mast 
cells and eosinophils, 
leading to 
accumulation of 
inflammatory cells and 
control of cytokine 
secretion 
• increased secretion of 
IL-31 by Th2 cells 
• none 
 
